Use of Rituximab in NHL Malt Type Pregnant in I° Trimester for Two Times

Administration of rituximab, one of the basic drugs for the therapy of B-cell lymphoproliferative diseases, during pregnancy has been suspected to cause developmental fetal events, particularly if given during the first trimester of pregnancy. Therefore, use in pregnancy is not permitted. Howe ver,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sica, Antonello, Vitiello, Paola, Papa, Alfonso, Calogero, Armando, Sagnelli, Caterina, Casale, Danilo, Mottola, Maria, Svanera, Gino, Dodaro, Concetta Anna, Martinelli, Erika, Troiani, Teresa, Ciardiello, Fortunato, Casale, Beniamino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884922/
https://www.ncbi.nlm.nih.gov/pubmed/31844674
http://dx.doi.org/10.1515/med-2019-0087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884922/
https://www.ncbi.nlm.nih.gov/pubmed/31844674
http://dx.doi.org/10.1515/med-2019-0087

Ejemplares similares